Jazz Pharmaceuticals (JAZZ) PT Raised to $263 at BofA Securities

January 9, 2026 4:57 AM EST Send to a Friend
BofA Securities analyst Jason Gerberry raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $263.00 (from $247.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login